Compile Data Set for Download or QSAR
Report error Found 5609 of ic50 data for polymerid = 336,50007491,50007492
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212110(US9290485, 142)
Affinity DataIC50: 0.0224nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212116(US9290485, 148)
Affinity DataIC50: 0.0300nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212114(US9290485, 146)
Affinity DataIC50: 0.0400nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM211977(US9290485, 9)
Affinity DataIC50: 0.0912nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212115(US9290485, 147)
Affinity DataIC50: 0.100nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212136(US9290485, 168)
Affinity DataIC50: 0.100nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582290(CHEMBL5082614 | US20230286958, Example 198)
Affinity DataIC50: 0.100nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582290(CHEMBL5082614 | US20230286958, Example 198)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212004(US9290485, 36)
Affinity DataIC50: 0.134nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM211974(US9290485, 6)
Affinity DataIC50: 0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212113(US9290485, 145)
Affinity DataIC50: 0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails
US Patent
PDB3D3D Structure (crystal)
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212134(US9290485, 166)
Affinity DataIC50: 0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212135(US9290485, 167)
Affinity DataIC50: 0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582291(CHEMBL5078294 | US20230286958, Example 200)
Affinity DataIC50: 0.200nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582291(CHEMBL5078294 | US20230286958, Example 200)
Affinity DataIC50: 0.200nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM696372(US12091399, Example 53 | 1-[(6-{5-azaspiro[2.3]hex...)
Affinity DataIC50: 0.200nMAssay Description:Human PKK (0.01 U/mL; Enzyme Research Laboratories) or rat PKK (0.625 nM; produced in-house) was incubated for 1 h at rt with 0.10 μM fluorogeni...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582287(CHEMBL5079850 | US20230286958, Example 41)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM211974(US9290485, 6)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human plasma kallikrein incubated for 1 hrsMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582288(CHEMBL5089406 | US20230286958, Example 136)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50597231(CHEMBL5201574)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human plasma kallikrein assessed as substrate hydrolysis using acetyl-K-P-R-AFC as substrate by spectrofluorometric analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582288(CHEMBL5089406 | US20230286958, Example 136)
Affinity DataIC50: 0.200nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582287(CHEMBL5079850 | US20230286958, Example 41)
Affinity DataIC50: 0.200nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582291(CHEMBL5078294 | US20230286958, Example 200)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582290(CHEMBL5082614 | US20230286958, Example 198)
Affinity DataIC50: 0.200nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPlasma kallikrein(Rat)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423170(US10501440, Example 2)
Affinity DataIC50: 0.300nMAssay Description:Human KLKB1 (0.01 U/mL; Enzyme Research Laboratories) or rat KLKB1 (0.625 nM; produced in-house) was incubated for 1 h at room temperature with 0.10 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM617993(US20230286958, Example 205 | US20230286958, Exampl...)
Affinity DataIC50: 0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM617991(US20230286958, Example 203 | 6-(3-Chloro-6-(difluo...)
Affinity DataIC50: 0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM528130(N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)ph...)
Affinity DataIC50: 0.300nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50574377(CHEMBL4853430)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human plasma kallikrein using H-Pro-Phe-AMC as fluorogenic substrate measured every 2 mins for 12 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM528122(3-amino-N-{[5-chloro-2-(1,2,3,4-tetrazol-1-yl)phen...)
Affinity DataIC50: 0.300nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582289(CHEMBL5076760 | US20230286958, Example 155)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM618006(US20230286958, Example 218 | US20230286958, Exampl...)
Affinity DataIC50: 0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM617832(US20230286958, Example 44)
Affinity DataIC50: 0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM617989(US20230286958, Example 201 | US20230286958, Exampl...)
Affinity DataIC50: 0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50621300(CHEMBL5417094)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human PKa using H-D-Pro-Phe-Arg-AFC peptide substrate measured after 60 mins by fluorometric assayMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50574379(CHEMBL4875151)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human plasma kallikrein using H-Pro-Phe-AMC as fluorogenic substrate measured every 2 mins for 12 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM617993(US20230286958, Example 205 | US20230286958, Exampl...)
Affinity DataIC50: 0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582289(CHEMBL5076760 | US20230286958, Example 155)
Affinity DataIC50: 0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM617940(US20230286958, Example 152 | 6-(3-Chloro-6-(difluo...)
Affinity DataIC50: 0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50597230(CHEMBL5208510)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human plasma kallikrein assessed as substrate hydrolysis using acetyl-K-P-R-AFC as substrate by spectrofluorometric analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50582286(CHEMBL5079924 | US20230286958, Example 45)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM263238(US9533987, example 23 | 5-amino-1-(4-pyrazol-1-ylm...)
Affinity DataIC50: 0.330nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM618017(US20230286958, Example 229 | 6-(3-Chloro-6-(difluo...)
Affinity DataIC50: 0.370nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212141(US9290485, 173)
Affinity DataIC50: 0.400nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Rat)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423180(US10501440, Example 10 | N-[(5R)-1-Amino-3-methyl-...)
Affinity DataIC50: 0.400nMAssay Description:Human KLKB1 (0.01 U/mL; Enzyme Research Laboratories) or rat KLKB1 (0.625 nM; produced in-house) was incubated for 1 h at room temperature with 0.10 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM50597234(CHEMBL5200467)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of human plasma kallikrein assessed as substrate hydrolysis using acetyl-K-P-R-AFC as substrate by spectrofluorometric analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
PubMed
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM696362(1-[(6-{3-azabicyclo[3.1.0]hexan-3-yl}-2- | US12091...)
Affinity DataIC50: 0.400nMAssay Description:Human PKK (0.01 U/mL; Enzyme Research Laboratories) or rat PKK (0.625 nM; produced in-house) was incubated for 1 h at rt with 0.10 μM fluorogeni...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM618028(US20230286958, Example 240 | 6-(3-Chloro-6-(difluo...)
Affinity DataIC50: 0.400nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM696336(N-{[3-chloro-2-fluoro-6-(1H-1,2,3,4- | US12091399,...)
Affinity DataIC50: 0.400nMAssay Description:Human PKK (0.01 U/mL; Enzyme Research Laboratories) or rat PKK (0.625 nM; produced in-house) was incubated for 1 h at rt with 0.10 μM fluorogeni...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM617827(US20230286958, Example 39)
Affinity DataIC50: 0.400nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

Displayed 1 to 50 (of 5609 total ) | Next | Last >>
Jump to: